Literature DB >> 10387938

Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease.

I Cacciola1, T Pollicino, G Squadrito, G Cerenzia, M E Orlando, G Raimondo.   

Abstract

BACKGROUND: Hepatitis B virus (HBV) infections in patients who lack detectable hepatitis B surface antigen (HBsAg) are called occult infections. Although such infections have been identified in patients with chronic hepatitis C liver disease, their prevalence and clinical significance are not known.
METHODS: With the polymerase chain reaction, we searched for HBV DNA in liver and serum samples from 200 HBsAg-negative patients with hepatitis C virus (HCV)-related liver disease (147 with chronic hepatitis, 48 with cirrhosis, and 5 with minimal histologic changes). One hundred of the patients had detectable antibodies to the HBV core antigen (anti-HBc); 100 were negative for all HBV markers. Eighty-three were treated with interferon alfa. We also studied 50 patients with liver disease who were negative both for HBsAg and for HCV markers. In six patients found to have occult HBV infection, we evaluated possible genomic rearrangements through cloning or direct sequencing procedures.
RESULTS: Sixty-six of the 200 patients with chronic hepatitis C liver disease (33 percent) had HBV sequences, as did 7 of the 50 patients with liver disease unrelated to hepatitis C (14 percent, P=0.01). Among the 66 patients, 46 were anti-HBc-positive and 20 were negative for all HBV markers (P<0.001). Twenty-two of these 66 patients (33 percent) had cirrhosis, as compared with 26 of the 134 patients with hepatitis C infection but no HBV sequences (19 percent, P=0.04). HBV sequences were detected in 26 of the 55 patients in whom interferon therapy was ineffective and 7 of the 28 patients in whom interferon therapy was effective (P=0.06). None of the sequenced HBV genomes had changes known to interfere with viral activity and gene expression.
CONCLUSIONS: Occult hepatitis B infection occurs frequently in patients with chronic hepatitis C liver disease and may have clinical significance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10387938     DOI: 10.1056/NEJM199907013410104

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  131 in total

1.  The science, economics, and effectiveness of combination therapy for hepatitis C.

Authors:  G Dusheiko; E Barnes; G Webster; S Whalley
Journal:  Gut       Date:  2000-08       Impact factor: 23.059

2.  The frequency and significance of isolated hepatitis B core antibody and the suggested management of patients.

Authors:  K A Al-Mekhaizeem; M Miriello; A H Sherker
Journal:  CMAJ       Date:  2001-10-16       Impact factor: 8.262

Review 3.  Occult hepatitis B: clinical implications and treatment decisions.

Authors:  Paul Schmeltzer; Kenneth E Sherman
Journal:  Dig Dis Sci       Date:  2010-10-07       Impact factor: 3.199

4.  Molecular characterization of occult and overt hepatitis B (HBV) infection in an HIV-infected person with reactivation of HBV after antiretroviral treatment interruption.

Authors:  S Bagaglio; L Porrino; A Lazzarin; G Morsica
Journal:  Infection       Date:  2010-06-09       Impact factor: 3.553

5.  Hepatitis B virus immunization among young injection drug users in San Francisco, Calif: the UFO Study.

Authors:  Paula J Lum; Kristen C Ochoa; Judith A Hahn; Kimberly Page Shafer; Jennifer L Evans; Andrew R Moss
Journal:  Am J Public Health       Date:  2003-06       Impact factor: 9.308

6.  Is hepatitis C virus positivity a contributing factor to occult hepatitis B virus infection in hemodialysis patients?

Authors:  Mehmet Kanbay; Gurden Gur; Ali Akcay; Haldun Selcuk; Ugur Yilmaz; Hande Arslan; Sedat Boyacioglu; Fatma Nurhan Ozdemir
Journal:  Dig Dis Sci       Date:  2006-09-15       Impact factor: 3.199

7.  Prevalence of occult HBV infection in haemodialysis patients with chronic HCV.

Authors:  Vedat Goral; Hamza Ozkul; Selahattin Tekes; Dede Sit; Ali Kemal Kadiroglu
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

8.  COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: a novel automated real-time PCR assay for quantification of HBV DNA in plasma.

Authors:  Tiziano Allice; Francesco Cerutti; Fabrizia Pittaluga; Silvia Varetto; Silvia Gabella; Alfredo Marzano; Alessandro Franchello; Giuseppe Colucci; Valeria Ghisetti
Journal:  J Clin Microbiol       Date:  2007-01-17       Impact factor: 5.948

9.  Immunogenicity of recombinant hepatitis B virus vaccine in patients with and without chronic hepatitis C virus infection: a case-control study.

Authors:  Naser Ebrahimi Daryani; Mohsen Nassiri-Toosi; Armin Rashidi; Iman Khodarahmi
Journal:  World J Gastroenterol       Date:  2007-01-14       Impact factor: 5.742

Review 10.  Current hepatitis B virus infection situation in Indonesia and its genetic diversity.

Authors:  Maria Inge Lusida; Yoshihiko Yano
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.